BUZZ-Checkpoint <a href="https://laohu8.com/S/LENZ">Therapeutics</a> rises after FDA approval of co's skin cancer drug ** Shares of drug developer Checkpoint Therapeutics CKPT.O rise 8.9% to $4 in premarket trading
** The U.S. FDA, on Friday, approved company's drug for treatment of a type of cancer of the outer layer of the skin
** The drug to be marketed under the brand name Unloxcyt is the company's first drug that has received approval
** Unloxcyt is part of a class of drugs, PD-L1 antibody, which works by binding to a protein called programmed death-ligand 1 that helps the body's immune system in killing cancer cells
** Company said it is "currently developing a commercial launch plan" for the drug
** Up to last close, stock up 60.3% YTD
(Reporting by Sneha S K)
((Sneha.SK@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments